



MARYLAND MEDICAID PHARMACY PROGRAM

No. 177
December 5, 2017

ADVISORY

*In an effort to give timely notice to the pharmacy community concerning important pharmacy topics, the Maryland Department of Health (MDH), **Maryland Medicaid Pharmacy Program (MMPP)** has developed the **Maryland Medicaid Pharmacy Program Advisory**. To expedite information timely to the pharmacy and prescriber communities, an email network has been established which incorporates the email lists of the Maryland Pharmacists Association, EPIC, CARE, Long Term Care Consultants, headquarters of all chain drugstores and prescriber associations and organizations. It is our hope that the information is disseminated to all interested parties. If you have not received this email through any of the previously noted parties or via MDH, please contact the MMPP representative at 410-767-1455.*

Carve-out of Ingrezza™

Effective Monday, November 27, 2017, Ingrezza™ (valbenazine) is carved-out from the HealthChoice managed care benefit and is covered by Maryland Medicaid fee-for-service (BIN: 610084, PCN: DRMDPROD and Group ID: MDMEDICAID). Claims for Ingrezza™ should be processed fee-for-service, just as claims for other carved-out mental health, substance use disorder and antiretroviral drugs.